Sanara Medtech Inc
SMTI
查看详细走势图
20.240USD
+0.200+1.00%
收盘 02/06, 16:00（美东）报价延迟15分钟
180.76M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.00%
5天
-8.00%
1月
-19.27%
6月
-18.39%
今年开始到现在
-13.32%
1年
-41.76%
查看详细走势图
TradingKey Sanara Medtech Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Sanara Medtech Inc当前公司基本面数据相对稳定，最新ESG披露属于行业中等水平。增长潜力很大。当前估值合理，在药品行业排名84/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价40.00。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Sanara Medtech Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Sanara Medtech Inc亮点
亮点风险
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
业绩高增长
公司营业收入稳步增长，连续3年增长89.06%
业绩增长期
公司处于发展阶段，最新年度总收入86.67M美元
利润高增长
公司净利润处于行业前列，最新年度总收入86.67M美元
估值高估
公司最新PE估值-4.65，处于3年历史高位
机构减仓
最新机构持股1.18M股，环比减少1.80%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值183.14K
分析师目标
根据
2
位分析师
买入
评级
40.000
目标均价
+97.63%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Sanara Medtech Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Sanara Medtech Inc简介
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
公司代码SMTI
公司Sanara Medtech Inc
CEOMuppalla (Suresh V)
网址https://sanaramedtech.com/
相关品种
